Comparison: IDRA is up 13% on phase 1/2 interim re
Post# of 72440
Posted On: 12/07/2015 2:56:55 PM
Comparison: IDRA is up 13% on phase 1/2 interim results, their stuff doesn't have serious safety problems and seems to help about half the people in the study. No MTD yet.
So if they're up 13% on that data, what do you think will happen when/if Kevetrin data is better than that?
So if they're up 13% on that data, what do you think will happen when/if Kevetrin data is better than that?
(0)
(0)Innovation Pharmaceuticals Inc (IPIX) Stock Research Links
Scroll down for more posts ▼